Compumedics Launches Five-Program Push to Unlock Value From Medical Technology
CMP: $0.250 +4.17% · MC: $48M
Compumedics is pursuing partnerships, licensing, co-development and strategic investment across five programs focused on Somfit, DWL and OrionMEG, aiming to accelerate commercialisation of its existing research and development; it says no transaction has been agreed and none is certain to proceed. The investor update also says the first Somfit D shipment to the US occurred in November, while the company acknowledges it missed FY26 revenue and EBITDA guidance. In FY27, Compumedics is targeting double-digit sales growth and EBITDA growth faster than sales.

Comments